Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 6, 2003, Pages 1037-1054

  Broderick, Patricia A ^a,b,c,d   Rahni, David N ^a,e   Zhou, Yueping ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c CITY COLLEGE OF NEW YORK   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PACE UNIVERSITY   (United States)

Author keywords

5 HT2 DA2 antagonism; Animal models of psychosis; Autoreceptors; BRODERICK PROBES microelectrode; Cocaine; Cocaine withdrawal; Depression; Dopamine; In vivo microvoltammetry; Locomotor (ambulatory) activity; Negative symptoms

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBON; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GAMMA BUTYROLACTONE; MONOAMINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPOLARIZATION; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ELECTROCHEMISTRY; EXPERIMENTAL RAT; FOLLOW UP; GROOMING; HABITUATION; HAIR; HYPOTHESIS; IN VIVO STUDY; INFRARED RADIATION; LOCOMOTION; MALE; MOBILIZATION; MONOAMINE RELEASE; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; ONLINE SYSTEM; POSTSYNAPTIC POTENTIAL; POTENTIOMETRY; PRESYNAPTIC NERVE; PSYCHOSIS; RAT; RAT STRAIN; SCHIZOPHRENIA; SENSOR; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; SNIFFING; STATISTICAL SIGNIFICANCE; STEREOTYPY; WITHDRAWAL SYNDROME;

EID: 0141792992     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00176-3     Document Type: Article

References (163)

1. Allen S.M., Freeman J.N., Davis W.M. Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan Syndrome. Pharmacol. Biochem. Behav. 59(2):1998;327-330.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, DSM IV-TR. 2000;American Psychiatric Association, Washington, DC.
3. Andrews C.M., Lucki I. Effects of cocaine on extracellular dopamine and serotonin levels in the nucleus accumbens. Psychopharmacology (Berlin). 155(3):2001;221-229.
4. 2 receptor blocking agent. Curr. Ther. Res. 40:1986;492-499.
5. Blum K., Trachtenberg M.C., Kowzlowski G.P. Cocaine therapy: the "reward cascade" link. Prof. Couns. 1989;327-335. (Jan./Feb.).
6. Bradberry C.W., Roth R.H. Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis. Neurosci. Lett. 103:1989;97-102.
7. Bradberry C.W., Nobiletti J.B., Elsworth J.D., Murphy B., Jatlow P., Roth R.H. Cocaine and cocaethylene: microdialysis comparison of brain drug levels and effects on dopamine and serotonin. J. Neurochem. 60:1993;1429-1435.
8. Brady K.T., Lydiard R.B., Malcolm R., Ballenger J.C. Cocaine-induced psychosis. J. Clin. Psychiatry. 52:1991;509-512.
9. Broderick P.A. Striatal neurochemistry of dynorphin-(1-13): in vivo electrochemical semidifferential analyses. Neuropeptides. 10:1987;369-386.
10. Broderick P.A. Distinguishing in vitro electrochemical signatures for norepinephrine and dopamine. Neurosci. Lett. 95:1988;275-280.
11. Broderick P.A. Characterizing stearate probes in vitro for the electrochemical detection of dopamine and serotonin. Brain Res. 495:1989;115-121.
12. Broderick P.A. State-of-the-art microelectrodes for in vivo voltammetry. Electroanalysis. 2:1990;241-251.
13. Broderick P.A. Cocaine; on-line analysis of an accumbens amine neuronal basis for psychomotor behavior. Pharmacol. Biochem. Behav. 40:1991;959-968.
14. Broderick P.A. In vivo voltammetric studies on release mechanisms for cocaine with γ-butyrolactone. Pharmacol. Biochem. Behav. 40:1991;969-975.
15. Broderick P.A. Cocaine's colocalized effects on synaptic serotonin and dopamine in ventral tegmentum in a reinforcement paradigm. Pharmacol. Biochem. Behav. 42:1992;889-898.
16. Broderick P.A. Distinguishing effects of cocaine (IV) and (SC) on mesoaccumbens dopamine and serotonin release with chloral hydrate anesthesia. Pharmacol. Biochem. Behav. 43:1992;929-937.
17. Broderick, P.A., 1999. Microelectrodes and their use in an electrochemical arrangement with telemetric application. U.S. Patent 5, 938, 903. Representative of approximately 20 patents and trademarks.
18. Broderick P.A. Microsensors detect cocaine neuroadaptation: serotonin release within basal ganglia is not rhythmic with movement. Massaro E.J., Schardein J.L., Broderick P.A., Schlaepfer T.E., Mattsson J.L. Handbook of Neurotoxicology. vol. 2:2001;323-367 Humana Press, Totowa, NJ.
19. Broderick P.A. Interleukin 1α alters hippocampal serotonin and norepinephrine release during open-field behavior in Sprague-Dawley animals: differences from the Fawn-Hooded animal model of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;1355-1372.
20. Broderick P.A., Phelix C.F. I: Serotonin (5-HT) within dopamine reward circuits signals open-field behavior. II: Basis of 5-HT-DA interaction in cocaine dysfunctional behavior. Neurosci. Biobehav. Rev. 21(3):1997;227-260.
21. 4 antagonist, PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J. Neural Transm. 105:1998;749-767.
22. Broderick P.A., Piercey M.F. Neurochemical and behavioral evidence supporting (+)-AJ 76 as a potential pharmacotherapy for cocaine abuse. J. Neural Transm. 105:1998;1307-1324.
23. Broderick P.A., Kornak E.P., Eng F., Wechsler R.W. Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat. Pharmacol. Biochem. Behav. 46:1993;715-722.
24. Broderick P.A., Penn-Erskine C., Charleton H., Green S., Okonji C. A four week follow-up study of serotonin (5-HT) and dopamine (DA) release in nucleus accumbens of animals behaving in an open-field paradigm, after acute cocaine administration. Soc. Neurosci. Abstr. 23:1997;1867.
25. Broderick P.A., Pacia S.V., Doyle W.K., Devinsky O. Monoamine neurotransmitters in resected hippocampal subparcellations from neocortical and mesial temporal lobe epilepsy patients: in situ microvoltammetric studies. Brain Res. 878:2000;49-63.
26. 1 receptors in nucleus accumbens. Psychopharmacology. 115:1994;110-114.
27. 1C sites. Eur. J. Pharmacol. 191:1990;93-96.
28. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry. 46(10):1999;1388-1395.
29. Carpenter W.T., Heinrich D.W., Wagman A.M.I. Deficit and non-deficit forms of schizophrenia, the concept. Am. J. Psychiatry. 145:1988;578-583.
30. Carroll F.I., Gray J.L., Abraham P., Kuzemko M.A., Lewin A.H., Boja J.W., Kuhar M.J. 3-Aryl-2-(3′-substituted-1′,2′,4′ -oxadiazol-5′-yl) tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin and norepinephrine transporters. J. Med. Chem. 36:1993;2886-2890.
31. Church W.H., Justice J.B. Jr., Byrd L.D. Extracellular dopamine in rat striatum following uptake inhibition by cocaine nomifensine and benztropine. Eur. J. Pharmacol. 139:1987;325-348.
32. Cohen S. Cocaine. JAMA. 231(1):1975;74-75.
33. Cools A.R., van Rossum J.M. Caudal dopamine and stereotype behaviour of cats. Arch. Int. Pharmacodyn. 187:1970;163-173.
34. Conloy R., Mahmoud R. A randomized double-blind study of risperidone and olanzepine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 158:2001;765-774.
35. Costall B., Naylor R.J. The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour. Eur. J. Pharmacol. 24:1973;8-24.
36. Cunningham K.A., Lakoski J.M. Electrophysiological effects of cocaine and procaine on dorsal raphe serotonin neurons. Eur. J. Pharmacol. 148:1988;457-462.
37. Dackis C.A., Gold M.S. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci. Biobehav. Rev. 9:1985;469-477.
38. De La Garza R. II, Cunningham K.A. The effects of the 5-hydroxytryptamine (1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. J. Pharmacol. Exp. Ther. 292(2):2000;610-617.
39. Delfs J.M., Schreiber L., Kelley A.E. Microinjection of cocaine into the nucleus accumbens elicits locomotor activation in the rat. J. Neurosci. 10(1):1990;303-310.
40. 2 receptor agonist, ritanserin. J. Neurochem. 59:1992;1459-1466.
41. de Wit H., Wise R.A. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide but not with the noradrenergic blockers, phentolamine or phenoxybenzamine. Can. J. Psychol. 31:1977;195-203.
42. 2C receptors in vivo. Pharmacol. Biochem. Behav. 71:2002;607-613.
43. Einhorn L.C., Johnsen P.A., White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J. Neurosci. 8:1988;100-112.
44. 2 receptor-mediated behavior and on extracellular concentrations of serotonin and dopamine. Pharmacol. Biochem. Behav. 49(1):1994;107-113.
45. Evenden J.L., Ryan C.N. Behavioral responses to psychomotor stimulant drugs: localization in the central nervous system. Pharmacol. Ther. 36:1988;151-172.
46. 2-dopamine receptor occupancy in schizophrenia patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 45(1):1988;71-76.
47. Filip M., Cunningham K.A. Serotonin 5-HT (2c) receptors in nucleus accumbens regulate expression of hyperlocomotive and discriminate stimulus effects of cocaine. Pharmacol. Biochem. Behav. 21(19):2002;7781-7787.
48. Fink-Jensen A. Novel pharmacological approaches to the treatment of schizophrenia. Dan. Med. Bull. 47(3):2000;151-167.
49. Foucault R., Broderick P.A., Rahni D.N., Lombardi J.R., Birke R.L. Neurotransmitter signatures: a correlation between Raman spectroscopy and microvoltammetric BRODERICK PROBES® NIH/NIGMS Conference and Abstract, New Orleans, LA:2002.
50. Gawin F., Kleber H. Pharmacological treatments of cocaine abuse. [Review] Psychiatr. Clin. North Am. 9:1986;573-583.
51. Gawin F.H., Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch. Gen. Psychiatry. 43:1986;104-113.
52. Goeders N.E., Smith J.E. Cortical dopaminergic involvement in cocaine reinforcement. Science. 221:1983;773-774.
53. Grabowski J., Rhoades H., Silverman P., Schmitz J.M., Stotts A., Creson D. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J. Clin. Psychopharmacol. 20(3):2000;305-310.
54. Hall F.S., Li X.F., Sora I., Xu F., Caron M., Lesch K.P., Murphy D.L., Uhl G.R. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience. 115:2002;153-161.
55. Heck A.H., Haffmans P.M., de Groot I.W., Hoencamp E. Risperidone versus haloperidol in psychiatric patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res. 46(2-3):2000;97-105.
56. 2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J. Neurochem. 73:1999;1711-1717.
57. 2C receptors. J. Pharmacol. Exp. Ther. 295:2000;226-232.
58. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. 124:1996;74-86.
59. Hertel P., Nomikos G.G., Schilstrom B., Arborelius L., Svensson T.H. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat brain. Psychopharmacology. 124:1997;74-76.
60. Hertel P., Nomikos G.G., Svensson T.H. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122:1997;1639-1646.
61. Hertel P., Lindblom N., Nomikos G.G., Svensson T.H. Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 22(5):1998;815-834.
62. Hertel P., Nomikos G.G., Svensson T.H. The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology. 38(8):1999;1175-1184.
63. Herve D., Pickel V.M., Joh T.H., Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435:1987;71-83.
64. Hope O., Lineen E., Okonji C., Green S., Saleem A., Aulakh C.S., Broderick P.A. Cocaine has remarkable nucleus accumbens effects on line, with behavior in the serotonin-deficient Fawn-Hooded rat. NIH/NIGMS Symposium, Washington, DC:1995.
65. Hurd Y.L., Ungerstedt U. Cocaine: an in vivo microdialysis of its acute action on dopamine neurotransmission in rat striatum. Synapse. 3:1989;48-54.
66. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858(2):2000;252-263.
67. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351(2):1998;163-171.
68. 2 receptor antagonist, on FOS protein expression in the rat forebrain. Pharmacol. Biochem. Behav. 63(4):1999;535-541.
69. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244:1988;685-693.
70. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-113.
71. Kalivas P.W., Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 5:1990;48-58.
72. Kane J.M. Pharmacologic treatment of schizophrenia. Biol. Psychiatry. 46(10):1999;1396-1408.
73. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52:2001;503-517.
74. Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can. J. Psychiatry. 39(Suppl. 2):1994;S46-S52.
75. Kelly P.H., Seviour P., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
76. King D.J. Drug treatment of the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 8(1):1998;33-42.
77. Kloss M.W., Rosen G.M., Rauckman E.J. Biotransformation of norcocaine to norcocaine nitroxide by rat brain microsomes. Psychopharmacology (Berlin). 84(2):1984;221-224.
78. Koe B.K. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp. Ther. 199:1976;649-661.
79. Koob G.F., Nestler E.J. The neurobiology of drug addiction. J. Neuropsychiatry Clin. Neurosci. 9:1997;482-497.
80. Kuroki T., Meltzer H.Y., Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
81. 2C receptors, a chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology. 13(2):1995;139-150.
82. Lemmens P., Brecher M., Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors are associated with extrapyramidal symptoms. Acta Psychiatr. Scand. 99:1999;160-170.
83. Leysen J.E., Gommeren W., Eens A., De Chaffoy De Coucelles J.C., Stoff J.C., Janssen P.A.J. Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 247:1988;661-670.
84. Leysen J.E., Janssen P.M.F., Gommeren W., Wynants J., Pauwels P.J., Janssen P.A.J. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics, risperidone and ocaperidone. Mol. Pharmacol. 41:1992;494-508.
85. 2 receptors. Psychopharmacology. 112:1993;S40-S54. (Suppl.).
86. Leysen J.E., Gommeren W., Schotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. Kane J.M., Moller H.-J., Awouters F. Serotonergic Mechanisms in Antipsychotic Treatment. 1996;51-76 Marcel Dekker, New York.
87. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry. 44(11):1998;1099-1117.
88. 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74:2000;693-701.
89. Mannens G., Huang M.L., Meuldermans W., Hendrickx J., Woestenborghs R., Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab. Dispos. 21:1993;1134-1141.
90. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 15:1994;825-835.
91. McKinzie D.L., Rodd Z.A., Dagon C.T., Murphy J.M., McBride W.J. Cocaine is self-administered into the shell region of the nucleus accumbens in Wistar rats. McGinty J.F. Advancing from the Ventral Striatum to the Extended Amygdala: Implications for Neuropsychiatry and Drug Abuse. 1999;788-791 New York Academy of Sciences, New York, NY.
92. McMahon L.R., Cunningham K.A. Antagonism of 5-hydroxytryptamine (4) receptors attenuates hyperactivity induced by cocaine: putative role for 5-hydroxytryptamine (4) receptors in the nucleus accumbens shell. J. Pharmacol. Exp. Ther. 291(1):1999;300-307.
93. McMahon L.R., Cunningham K.A. Antagonism of 5-hydroxytryptamine (2A) receptors attenuates the behavioral effects of cocaine in rats. J. Pharmacol. Exp. Ther. 297(1):2001;357-363.
94. McMahon L.R., Filip M., Cunningham K.A. Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and (5-HT)2C receptors. J. Neurosci. 21(19):2001;7781-7787.
95. Megens A.A., Awouters F.H., Meert T.F., Schellekens K.H., Niemegeers C.J., Janssen P.A. Pharmacological profile of the new potent neuroleptic, ocaperidone (R 79598). J. Pharmacol. Exp. Ther. 260(1):1992;146-159.
96. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;518-527.
97. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
98. Meltzer H.Y. Dimensions of outcome with clozapine. Br. J. Psychiatry. 160(Suppl. 17):1992;S46-S53.
99. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;S106-S115. (Suppl.).
100. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43:1991;587-604.
101. 2 receptor occupancy: implications for antipsychotic action. Eur. J. Pharmacol. 216:1992;67-71.
102. Mendoza R., Miller B.L., Mena I. Emergency room evaluation of cocaine-associated neuropsychiatric disorders. Recent Dev. Alcohol. 10:1992;73-87.
103. Mets B., Diaz J., Soo E., Jamdar S. Cocaine, norcocaine, ecgonine methylester and benzoylecgonine pharmacokinetics in the rat. Life Sci. 65(12):1999;1317-1328.
104. Miller B.L., Mena I., Giombetti R., Villanueve-Meyer J., Djenderedjian A.H. Neuropsychiatric effects of cocaine: SPECT measurements. J. Addict. Dis. 11:1992;47-58.
105. Misra A.L., Nayak P.K., Patel M.N., Vadlamani N.I., Mule S.J. Identification of norcocaine as a metabolite of (3H)-cocaine in rat brain. Experientia. 30(11):1974;1312-1314.
106. Misra A.L., Vadlamani N.I., Bloch R., Nayak P.K., Mule S.J. Physiologic disposition and metabolism of (3H) ecgonine (cocaine metabolite) in the rat. Res. Commun. Chem. Pathol. Pharmacol. 8(1):1974;55-63.
107. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone and haloperidol in vivo in the rodent and non-human primate brain using 18f-fallypride. Neuropsychopharmacology. 25(4):2001;476-488.
108. Myers J.E., Thase M.E. Risperidone: review of its therapeutic utility in depression. Psychopharmacol. Bull. 35(4):2001;109-129.
109. Nambudin D.E., Young R.C. A case of late-onset crack dependence and subsequent psychosis in the elderly. J. Subst. Abuse Treat. 8:1991;253-255.
110. Nayak P.K., Misra A.L., Mule S.J. Physiological disposition and biotransformation of (3H) cocaine in acutely and chronically treated rats. J. Pharmacol. Exp. Ther. 196(3):1976;556-569.
111. Newton T.F., Ling W., Kalechstein A.D., Uslaner J., Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 102(3):2001;227-233.
112. Ng J.P., Hubert G.W., Justice J.B. Jr. Increased stimulated release and uptake of dopamine in nucleus accumbens after repeated cocaine administration as measured by in vivo voltammetry. J. Neurochem. 56:1991;1485-1492.
113. Parsons L.H., Koob G.F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J. Pharmacol. Exp. Ther. 274:1995;1182-1191.
114. Parsons L.H., Koob G.F., Weiss F. Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration. Behav. Brain Res. 73(1-2):1996;225-228.
115. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A Stereotaxic Atlas of the Rat Brain. 1979;Plenum Press, New York.
116. Phelix C.F., Broderick P.A. Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res. Rev. 37:1995;37-40.
117. Pijnenburg A.J.J., Honig W.M.M., van Rossum J.M. Effects of antagonists upon locomotor stimulation induced by injection of dopamine and noradrenaline into the nucleus accumbens of nialamide-pretreated rats. Psychopharmacologia. 41:1975;175-180.
118. Price L.H., Charney D.S., Delgado P.L., Heninger G.R. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology (Berlin). 100:2001;3-12.
119. Reith M.E., Li M.Y., Yan Q.S. Extracellular dopamine, norepinephrine and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berlin). 134:1997;309-317.
120. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
121. Roberts D.C.S., Koob G.F. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol. Biochem. Behav. 17:1982;901-904.
122. Rosse R.B., Collins J.P. Jr., Fay-McCarthy M., Alim T.N., Wyatt R.J., Deutsch S.I. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin. Neuropharmacol. 17:1994;359-369.
123. Ryan L., Martone M., Linder J., Groves P. Cocaine, in contrast to D-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats. Life Sci. 43:1988;1403-1409.
124. Satel S.L., Edell W.S. Cocaine-induced paranoia and psychosis proneness. Am. J. Psychiatry. 148:1991;1708-1711.
125. Satel S.L., Seibyl J.P., Charney D.S. Prolonged cocaine psychosis implies underlying major psychopathology. J. Clin. Psychiatry. 52:1991;349-350.
126. Schotte A., Janssen P.F.M., Megens A.A.U.P., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631:1993;191-202.
127. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
128. Seecof R., Tennant F.S. Jr. Subjective perceptions to the intravenous "rush" of heroin and cocaine in opioid addicts. Am. J. Drug Alcohol Abuse. 12(1-2):1986;79-87.
129. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133.
130. Seiden L.S., Kleven M.S. Lack of toxic effects of cocaine on dopamine and serotonin neurons in rat brain. Clouet D., Asghar K., Brown R. Mechanisms of Cocaine Abuse and Toxicity. 1988;276-289 DHHS Pub (ADM) 88-1585, Rockville, MD.
131. Sherer M.A., Kumor K.M., Cone E.J., Jaffe J.H. Suspiciousness induced by four-hour intravenous infusions of cocaine. Preliminary findings. Arch. Gen. Psychiatry. 45:1988;673-677.
132. Smelson D.A., Roy A., Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can. J. Psychiatry. 42(9):1997;984.
133. Smelson D.A., Losonczy M.F., Davis C.W., Kaune M., Williams J., Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can. J. Psychiatry. 47(7):2002;671-675.
134. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
135. Spealman R.D., Bergman J., Madras B.K., Kamien J.B., Melia K.F. Role of D1 and D2 dopamine receptors in the behavioral effects of cocaine. Neurochem. Int. 20:1992;S147-S152. (Suppl.).
136. Stahl S.M. Essential Psychopharmacology. 2nd ed. 2000;Cambridge Univ. Press, New York.
137. Steinbusch H.W.M. Distribution of serotonin-immunoreactivity in the central nervous system of the rat cell bodies and terminals. Neuroscience. 6:1981;557-618.
138. 2 receptor binding study of risperidone and haloperidol. Pharmacol. Biochem. Behav. 47:1994;553-557.
139. 2 receptor occupancy. Neuropsychopharmacology. 12:1995;57-64.
140. Sun L., Lau C.E. Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats. Drug Metab. Dispos. 29(9):2001;1183-1189.
141. 2 receptors as assessed by in vitro and in vivo binding. Eur. J. Pharmacol. 254:1994;73-81.
142. Tarazi F.I., Zhang K., Baldessarini R.J. Olanzepine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci. Lett. 287:2000;81-84.
143. Taylor W.A., Staby A.E. Acute treatment of alcohol and cocaine emergencies. Recent Dev. Alcohol. 10:1992;179-191.
144. Teneud L.M., Baptista T., Murzi E., Hoebel B.G., Hernandez L. Systemic and local cocaine increase extracellular serotonin in the nucleus accumbens. Pharmacol. Biochem. Behav. 53(3):1996;747-752.
145. 2A antagonism of cocaine-induced facilitation of brain stimulation reward. Pharmacol. Biochem. Behav. 59(2):1998;275-280.
146. Tsuang J.W., Eckman T., Marder S., Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J. Clin. Psychopharmacol. 22(6):2002;629-630.
147. Tueth M.J. High incidence of psychosis in cocaine intoxication and preventing violence in the ED. Am. J. Emerg. Med. 11:1993;676.
148. Turgay A., Binder C., Snyder R., Fisman S. Long term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with sub-average IQ's. Pediatrics. 110(3):2002;34.
149. Van Bockstaele E.J., Pickel V.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J. Comp. Neurol. 334:1993;603-617.
150. Van Bockstaele E.J., Cestari D.M., Pickel V.M. Synaptic structure and connectivity of serotonin in the ventral tegmental area: potential sites for modulation of mesolimbic dopamine neurons. Brain Res. 674:1994;307-322.
151. Van Campenhout N., De Haes P., Meer T.F. Inability of antipsychotics to antagonize the cueing properties of cocaine in rats. Pharmacol. Biochem. Behav. 64(2):1999;435-438.
152. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69(1):1997;182-190.
153. Wadenberg M.L., Sollman A., VanderSpek S.C., Kapur S. Dopamine D (2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 25(5):2001;633-641.
154. 3 receptor and autoreceptor preferring antagonists (+) -AJ76 and (+)-UH232: a microdialysis study. Eur. J. Pharmacol. 242:1993;151-163.
155. Weinberger D.R., Berman K.F., Suddath R., Fuller-Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic imaging and regional cerebral blood flow study of discordant monozygotic twins. Am. J. Psychiatry. 149:1992;898-907.
156. Weiner I., Gaisler I., Schiller D., Green A., Zuckerman L., Joel D. Screening of antipsychotic drugs in animal models. Drug Dev. Res. 50:2000;235-249.
157. Williams R. Optimal dosing with risperidone: updated recommendations. J. Clin. Psychiatry. 62(4):2001;282-289.
158. 2-type contributions to psychomotor sensitization and reward: implications for pharmacological treatment strategies. Clin. Neuropharmacol. 18(Suppl. 1):1995;S74-S83.
159. Wise R.A., Bozarth M.A. A psychostimulant theory of addiction. Psychol. Rev. 94:1987;469-492.
160. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu. Rev. Psychol. 40:1989;191-225.
161. 2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br. J. Pharmacol. 99:1990;221-223.
162. 2A receptor stimulation in rats pretreated with intermittent cocaine. Brain Res. 863(1-2):2000;254-258.
163. Yeats W.B. The collected poems of W.B. Yeats. 1956;Macmillan, New York, NY.